Azithromycin is an antibiotic used to treat bacterial infections such as respiratory infections, ear infections, and sexually transmitted infections. It works by stopping bacteria from growing and multiplying.[2] Zithromax is currently approved and in use across 121 indications[4].[1]
Zithromax is one of 1519 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
1931 competitors in COVID-19
Zithromax
Spikevax
Tricor
Precedex
Rayaldee
Statin
Olokizumab
Opaganib
Hymecromone
Saliva Collection
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Nov 1, 1991
ZITHROMAX
NDA NDA050670
Sep 28, 1994
ZITHROMAX
NDA NDA050693
Oct 19, 1995
ZITHROMAX
NDA NDA050710
Jun 12, 1996
ZITHROMAX
NDA NDA050730
Jul 18, 1996
ZITHROMAX
NDA NDA050711
Jan 30, 1997
ZITHROMAX
NDA NDA050733
May 24, 2002
ZITHROMAX
NDA NDA050784
Jun 10, 2005
ZMAX
NDA NDA050797
Dec 19, 2006
AZITHROMYCIN
NDA NDA050809
Apr 27, 2007
AZASITE
NDA NDA050810
Sources
Details